Altana denies delay of Daxas launch

Germany's Altana is denying rumors that it is planning to delay the US launch of its respiratory drug Daxas. Its stock has been hit by talk of a delay. The drug, which has been tapped as a potential blockbuster, is currently in a Phase III US trial. European regulators are considering Altana's marketing application.

- read this story from AFX for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.